ATE254595T1 - 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten - Google Patents
2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheitenInfo
- Publication number
- ATE254595T1 ATE254595T1 AT98946706T AT98946706T ATE254595T1 AT E254595 T1 ATE254595 T1 AT E254595T1 AT 98946706 T AT98946706 T AT 98946706T AT 98946706 T AT98946706 T AT 98946706T AT E254595 T1 ATE254595 T1 AT E254595T1
- Authority
- AT
- Austria
- Prior art keywords
- inflammatory
- prevention
- pharmaceutical compositions
- therapeutic treatment
- tetralin
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- ISWMKVVVEVKRMT-UHFFFAOYSA-N 1-(7-amino-3-methyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethanone Chemical compound C1C(N)CCC2=C1C=C(C(=O)C)C(C)=C2 ISWMKVVVEVKRMT-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000007170 pathology Effects 0.000 abstract 2
- LCGFVWKNXLRFIF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-amine Chemical class C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97RM000568A IT1294931B1 (it) | 1997-09-22 | 1997-09-22 | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella |
| PCT/IT1998/000252 WO1999015494A1 (en) | 1997-09-22 | 1998-09-22 | 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE254595T1 true ATE254595T1 (de) | 2003-12-15 |
Family
ID=11405257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98946706T ATE254595T1 (de) | 1997-09-22 | 1998-09-22 | 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7041703B2 (de) |
| EP (1) | EP1017667B1 (de) |
| JP (1) | JP4181301B2 (de) |
| KR (1) | KR100583805B1 (de) |
| CN (1) | CN1145606C (de) |
| AT (1) | ATE254595T1 (de) |
| AU (1) | AU738565B2 (de) |
| BR (1) | BR9812368A (de) |
| CA (1) | CA2303943A1 (de) |
| DE (1) | DE69819922T2 (de) |
| DK (1) | DK1017667T3 (de) |
| ES (1) | ES2210820T3 (de) |
| IT (1) | IT1294931B1 (de) |
| NZ (1) | NZ503492A (de) |
| PT (1) | PT1017667E (de) |
| WO (1) | WO1999015494A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1294931B1 (it) * | 1997-09-22 | 1999-04-23 | Sigma Tau Ind Farmaceuti | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella |
| IT1317050B1 (it) * | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Tetraline 2,6,7-sostituite utili per la preparazione di un medicamentoad attivita' inibitrice della fosfodiesterasi iv. |
| IT1317049B1 (it) * | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. |
| PL365608A1 (en) * | 2000-08-14 | 2005-01-10 | Teva Pharmaceutical Industries Ltd. | Preparation of risperidone |
| US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| GB0504314D0 (en) * | 2005-03-02 | 2005-04-06 | Glaxo Group Ltd | Novel polymorph |
| CN101768086B (zh) * | 2008-12-29 | 2014-03-26 | 北京富龙康泰生物技术有限公司 | 氨基甲醇衍生物及其盐类化合物及其合成方法和其药物用途 |
| WO2019052980A1 (en) | 2017-09-14 | 2019-03-21 | F. Hoffmann-La Roche Ag | NOVEL COMPOUND FOR USE IN THE MANUFACTURE OF MEDICAMENTS |
| CN115724758B (zh) * | 2021-08-24 | 2024-12-27 | 杭州中美华东制药有限公司 | 喜树碱衍生物中间体及其合成方法和利用中间体合成喜树碱衍生物的方法 |
| CN117088786B (zh) * | 2022-05-12 | 2025-09-19 | 上海医药工业研究院有限公司 | 一种依沙替康中间体及其制备方法 |
| CN116924896A (zh) * | 2023-06-25 | 2023-10-24 | 北京蓝博特科技有限公司 | 一种萘酮类化合物的合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919316A (en) * | 1974-08-05 | 1975-11-11 | Lilly Co Eli | 2-Aminodichlorotetralins |
| DE2752659A1 (de) * | 1976-12-07 | 1978-06-08 | Sandoz Ag | Neue tetralinderivate, ihre herstellung und verwendung |
| US4448990A (en) * | 1982-11-16 | 1984-05-15 | Eli Lilly And Company | Hydroxyaminotetralincarboxamides |
| DE3660959D1 (de) * | 1985-06-26 | 1988-11-24 | Smithkline Beckman Corp | Benz-trisubstituted 2-aminotetralins |
| IT1241988B (it) * | 1990-06-15 | 1994-02-02 | Sigma Tau Ind Farmaceuti | 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono |
| IT1242043B (it) * | 1990-12-21 | 1994-02-02 | Sigma Tau Ind Farmaceuti | Derivati della 1,2,3,4,-tetraidronaftilammina ad attivita' nootropica e composizioni farmaceutiche che li contengono. |
| US5438150A (en) * | 1994-04-26 | 1995-08-01 | Syntex (U.S.A.) Inc. | Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives |
| IT1278045B1 (it) * | 1995-03-09 | 1997-11-17 | Sigma Tau Ind Farmaceuti | Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di |
| IT1290910B1 (it) * | 1997-02-03 | 1998-12-14 | Sigma Tau Ind Farmaceuti | 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive |
| IT1294932B1 (it) * | 1997-09-22 | 1999-04-23 | Sigma Tau Ind Farmaceuti | Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie |
| IT1294931B1 (it) * | 1997-09-22 | 1999-04-23 | Sigma Tau Ind Farmaceuti | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella |
-
1997
- 1997-09-22 IT IT97RM000568A patent/IT1294931B1/it active IP Right Grant
-
1998
- 1998-09-22 JP JP2000512805A patent/JP4181301B2/ja not_active Expired - Fee Related
- 1998-09-22 DK DK98946706T patent/DK1017667T3/da active
- 1998-09-22 ES ES98946706T patent/ES2210820T3/es not_active Expired - Lifetime
- 1998-09-22 WO PCT/IT1998/000252 patent/WO1999015494A1/en not_active Ceased
- 1998-09-22 BR BR9812368-8A patent/BR9812368A/pt not_active Application Discontinuation
- 1998-09-22 AU AU93662/98A patent/AU738565B2/en not_active Ceased
- 1998-09-22 EP EP98946706A patent/EP1017667B1/de not_active Expired - Lifetime
- 1998-09-22 AT AT98946706T patent/ATE254595T1/de not_active IP Right Cessation
- 1998-09-22 KR KR1020007003077A patent/KR100583805B1/ko not_active Expired - Fee Related
- 1998-09-22 DE DE69819922T patent/DE69819922T2/de not_active Expired - Fee Related
- 1998-09-22 PT PT98946706T patent/PT1017667E/pt unknown
- 1998-09-22 NZ NZ503492A patent/NZ503492A/xx unknown
- 1998-09-22 CA CA002303943A patent/CA2303943A1/en not_active Abandoned
- 1998-09-22 CN CNB988104598A patent/CN1145606C/zh not_active Expired - Fee Related
-
2000
- 2000-03-22 US US09/533,381 patent/US7041703B2/en not_active Expired - Fee Related
-
2001
- 2001-03-26 US US09/816,317 patent/US6849663B2/en not_active Expired - Fee Related
-
2003
- 2003-04-08 US US10/408,122 patent/US20030229148A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4181301B2 (ja) | 2008-11-12 |
| CN1276782A (zh) | 2000-12-13 |
| DK1017667T3 (da) | 2004-03-29 |
| EP1017667A1 (de) | 2000-07-12 |
| PT1017667E (pt) | 2004-04-30 |
| DE69819922D1 (de) | 2003-12-24 |
| BR9812368A (pt) | 2000-09-19 |
| KR20010030671A (ko) | 2001-04-16 |
| AU9366298A (en) | 1999-04-12 |
| JP2001517649A (ja) | 2001-10-09 |
| HK1029099A1 (en) | 2001-03-23 |
| US7041703B2 (en) | 2006-05-09 |
| DE69819922T2 (de) | 2004-09-02 |
| ITRM970568A1 (it) | 1999-03-22 |
| NZ503492A (en) | 2002-08-28 |
| US20030158266A1 (en) | 2003-08-21 |
| US20030229148A1 (en) | 2003-12-11 |
| EP1017667B1 (de) | 2003-11-19 |
| WO1999015494A1 (en) | 1999-04-01 |
| CA2303943A1 (en) | 1999-04-01 |
| IT1294931B1 (it) | 1999-04-23 |
| ES2210820T3 (es) | 2004-07-01 |
| US6849663B2 (en) | 2005-02-01 |
| CN1145606C (zh) | 2004-04-14 |
| KR100583805B1 (ko) | 2006-05-26 |
| AU738565B2 (en) | 2001-09-20 |
| US20020123652A1 (en) | 2002-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO307968B1 (no) | Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav | |
| DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
| EA199700135A1 (ru) | Ингибиторы клеточной адгезии | |
| ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE69905368D1 (en) | Oxydiertes thymosin beta 4 | |
| NL300258I2 (nl) | Farmaceutische samenstelling voor toepassing in debehandeling van. | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| YU37602A (sh) | Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns | |
| ID22746A (id) | Senyawa-senyawa baru | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| ATE265857T1 (de) | Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie | |
| MX9800348A (es) | Inhibidores de adhesion celular. | |
| ITMI931649A1 (it) | Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico | |
| ATE254595T1 (de) | 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten | |
| IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
| DE69822297D1 (de) | Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DE60112768D1 (de) | Behandlung von entzündlichen erkrankungen | |
| ES2190581T3 (es) | 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico. | |
| FI961494L (fi) | Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi | |
| DE69737088D1 (de) | Therapeutisches agens zur behandlung von fiv infektionen | |
| PT907737E (pt) | Muteina da il-6 | |
| ES2167942T3 (es) | Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1017667 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |